Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Cabotegravir

FDA-approved product (suspension, extended release, intramuscular), marketed as Apretude, Vocabria.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Cabotegravir
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • HIV infection
  • HIV-1 infection
  • Viral disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Integrase inhibitors
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J05AJ04

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA, E. coli and K. pneumoniae. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA58.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli54.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae45.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis62.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Cabotegravir in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-9.4 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-9.1 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-10.2 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-9.3 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Cabotegravir with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • PrEP-LANA (Pre-exposure Prophylaxis- Long-acting Novel Antiviral Agent)

    NCT07620730 · start 2026-10

    Registered record
    Registry ID
    NCT07620730
    Conditions
    PrEP; PrEP Adherence Experiences; PrEP Adherence Perspectives; PrEP Uptake; Equity; Community Setting
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Not yet recruiting
    Start
    2026-10
    Completion
    2028-06
    Enrolment
    220

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPrEP; PrEP Adherence Experiences; PrEP Adherence Perspectives; PrEP Uptake +2 more
    InterventionNot recorded
    PhaseNot recorded
    Registry statusNot yet recruiting

  • NOTRE: Optimizing Long-Acting Pre-Exposure Prophylaxis and Medications for Opioid Use Disorder Interventions in Carceral Settings

    NCT06854029 · start 2026-09-01

    Registered record
    Registry ID
    NCT06854029
    Conditions
    HIV Infections; Opioid Use Disorder; Incarceration; Lens
    Interventions
    Cabotegravir Injection; Cabotegravir Pill; Buprenorphine injection; Buprenorphine Pill
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Not yet recruiting
    Start
    2026-09-01
    Completion
    2030-06-01
    Enrolment
    450

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections; Opioid Use Disorder; Incarceration; Lens
    InterventionCabotegravir Injection; Cabotegravir Pill; Buprenorphine injection; Buprenorphine Pill
    PhasePhase 4
    Registry statusNot yet recruiting

  • Linking Youth to Pre-Exposure Prophylaxis (PrEP) Services

    NCT07438041 · start 2026-07-27

    Registered record
    Registry ID
    NCT07438041
    Conditions
    HIV; PrEP; PrEP Adherence
    Interventions
    LYPS; Enhanced Standard of Care
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Not yet recruiting
    Start
    2026-07-27
    Completion
    2028-12-15
    Enrolment
    272

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV; PrEP; PrEP Adherence
    InterventionLYPS; Enhanced Standard of Care
    PhaseNot applicable
    Registry statusNot yet recruiting

  • Cabotegravir-Hormone PK/PD Interactions for HIV Prevention

    NCT07672717 · start 2026-07-07

    Registered record
    Registry ID
    NCT07672717
    Conditions
    HIV; Prophylaxis; Injectable
    Interventions
    Cabotegravir Injectable Suspension (CAB LA)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Recruiting
    Start
    2026-07-07
    Completion
    2031-12
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV; Prophylaxis; Injectable
    InterventionCabotegravir Injectable Suspension (CAB LA)
    PhasePhase 1
    Registry statusRecruiting

  • PERsistance of Long-Acting inJEctable CAB+RPV in a Cohort of Virologically-suppressed PLWH: a Real-life Study

    NCT07579546 · start 2026-06-01

    Registered record
    Registry ID
    NCT07579546
    Conditions
    HIV-1-infection
    Interventions
    Cabotegravir/Rilpivirine
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Not yet recruiting
    Start
    2026-06-01
    Completion
    2027-06-01
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-1-infection
    InterventionCabotegravir/Rilpivirine
    PhaseNot recorded
    Registry statusNot yet recruiting

  • Long-Acting Cabotegravir and Rilpivirine in People Living With HIV-1 Subtype A6: A Real-World Retrospective Study

    NCT07370649 · start 2026-05-12

    Registered record
    Registry ID
    NCT07370649
    Conditions
    Human Immunodeficiency Virus (HIV)-1 Infection; HIV-1 Subtype A6 Infection; HIV-1 Subtype B Infection; Virologically Suppressed HIV-1 Infection Receiving Long-Acting Antiretroviral Therapy
    Interventions
    Cabotegravir Plus Rilpivirine Long-Acting Injectable
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2026-05-12
    Completion
    2027-03
    Enrolment
    250

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHuman Immunodeficiency Virus (HIV)-1 Infection; HIV-1 Subtype A6 Infection; HIV-1 Subtype B Infection; Virologically Suppressed HIV-1 Infection Receiving Long-Acting Antiretroviral Therapy
    InterventionCabotegravir Plus Rilpivirine Long-Acting Injectable
    PhaseNot recorded
    Registry statusRecruiting

  • Project SPEED - Streamlined Protocol for Early Engagement and Delivery of HIV Prevention With Long-acting Injectable Cabotegravir: A Nurse-driven Protocol

    NCT07346508 · start 2026-04-01

    Registered record
    Registry ID
    NCT07346508
    Conditions
    HIV (Human Immunodeficiency Virus)
    Interventions
    nurse-driven protocol for delivering Long-acting Injectable Cabotegravir (LAI-CAB) for HIV pre-exposure prophylaxis (PrEP)
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Not yet recruiting
    Start
    2026-04-01
    Completion
    2028-12-31
    Enrolment
    250

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV (Human Immunodeficiency Virus)
    Interventionnurse-driven protocol for delivering Long-acting Injectable Cabotegravir (LAI-CAB) for HIV pre-exposure prophylaxis (PrEP)
    PhaseNot applicable
    Registry statusNot yet recruiting

  • CABOTEGRAVIR/LENACAPAVIR DUAL LONG ACTING THERAPY (COHORT IMEA 074)

    NCT07402044 · start 2026-03-15

    Registered record
    Registry ID
    NCT07402044
    Conditions
    CABOTEGRAVIR; LENACAPAVIR
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Not yet recruiting
    Start
    2026-03-15
    Completion
    2028-03-15
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCABOTEGRAVIR; LENACAPAVIR
    InterventionNot recorded
    PhaseNot recorded
    Registry statusNot yet recruiting

  • Long-acting Cabotegravir Injectable Pre-exposure Prophylaxis for People Who Inject Drugs

    NCT07199335 · start 2026-02-24

    Registered record
    Registry ID
    NCT07199335
    Conditions
    HIV; Substance Use Disorder (SUD); Injection Drug Use
    Interventions
    APRETUDE (cabotegravir)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2026-02-24
    Completion
    2028-12
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV; Substance Use Disorder (SUD); Injection Drug Use
    InterventionAPRETUDE (cabotegravir)
    PhasePhase 4
    Registry statusRecruiting

  • Switch From Oral Therapy to Long-acting Injectable Cabotegravir + Rilpivirine

    NCT05835635 · start 2025-05-01

    Registered record
    Registry ID
    NCT05835635
    Conditions
    Patient Satisfaction; Patient Preference; Quality of Life; Acceptability of Health Care
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Not yet recruiting
    Start
    2025-05-01
    Completion
    2026-05-01
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPatient Satisfaction; Patient Preference; Quality of Life; Acceptability of Health Care
    InterventionNot recorded
    PhaseNot recorded
    Registry statusNot yet recruiting

  • CAbotégravir LENacapavir DUal Long Acting

    NCT06657885 · start 2025-01-15

    Registered record
    Registry ID
    NCT06657885
    Conditions
    HIV1 Infection; Multi-treated Patients Who Have Received Multiple Lines of Antiretroviral Treatment; CABOTEGRAVIR; LENACAPAVIR; Stable Oral Antiretroviral Treatment for at Least 6 Months
    Interventions
    his is a prospective, single-arm, multicentre, non-randomised phase II, pilot study designed to achieve or maintain virological success in participants who meet the prescribing criteria for lenacapavi
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Withdrawn
    Start
    2025-01-15
    Completion
    2026-09-15
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV1 Infection; Multi-treated Patients Who Have Received Multiple Lines of Antiretroviral Treatment; CABOTEGRAVIR; LENACAPAVIR +1 more
    Interventionhis is a prospective, single-arm, multicentre, non-randomised phase II, pilot study designed to achieve or maintain virological success in participants who meet the prescribing criteria for lenacapavi
    PhasePhase 2
    Registry statusWithdrawn

  • Use of Long-Acting Injectable Cabotegravir/Rilpivirine for the Treatment of HIV in Belgium

    NCT06424964 · start 2025-01-13

    Registered record
    Registry ID
    NCT06424964
    Conditions
    Human Immunodeficiency Virus
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2025-01-13
    Completion
    2025-07
    Enrolment
    600

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHuman Immunodeficiency Virus
    InterventionNot recorded
    PhaseNot recorded
    Registry statusRecruiting

  • Identification of Barriers and Facilitators of Implementation of the Out-of-Hospital Administration of the Long- Acting Combination Cabotegravir+Rilpivirina.

    NCT06643897 · start 2024-07-16

    Registered record
    Registry ID
    NCT06643897
    Conditions
    HIV-1-infection
    Interventions
    Qualitative Interview
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2024-07-16
    Completion
    2024-10-23
    Enrolment
    13

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-1-infection
    InterventionQualitative Interview
    PhaseNot applicable
    Registry statusCompleted

  • IMplementation of CAB+RPV LA for People With HIV in Non-Metropolitan Areas

    NCT06451341 · start 2024-07-01

    Registered record
    Registry ID
    NCT06451341
    Conditions
    HIV
    Interventions
    Acceptability of Intervention Measure (AIM); Intervention Appropriateness Measure (IAM); Feasibility of Intervention Measure (FIM); HIV Stigma Scale Questionnaire; HIV Treatment Satisfaction Questionnaire status version (HIVTSQs12); HIV Treatment Satisfaction Questionnaire change version (HIVTSQc12); Needs and Barriers Assessment; Pre-visit Outreach; Qualitative interview - patient participants; Staff education; Staff Month 7 and 15 Survey - Staff Burden and Engagement; Qualitative interview - staff
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Active not recruiting
    Start
    2024-07-01
    Completion
    2028-05
    Enrolment
    75

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV
    InterventionAcceptability of Intervention Measure (AIM); Intervention Appropriateness Measure (IAM); Feasibility of Intervention Measure (FIM); HIV Stigma Scale Questionnaire +8 more
    PhaseNot recorded
    Registry statusActive not recruiting

  • UNCPM 22314 - Pregnancy, Infant and Maternal Health Outcomes Study

    NCT06158126 · start 2024-04-17

    Registered record
    Registry ID
    NCT06158126
    Conditions
    Pre-exposure Prophylaxis; HIV Prevention; Pregnancy Related
    Interventions
    Initiating daily oral PrEP during pregnancy; Already using daily oral PrEP at the time of pregnancy diagnosis; Initiating injectable PrEP during pregnancy; Already using injectable PrEP (CAB-LA) at the time of pregnancy diagnosis
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2024-04-17
    Completion
    2027-12
    Enrolment
    621

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPre-exposure Prophylaxis; HIV Prevention; Pregnancy Related
    InterventionInitiating daily oral PrEP during pregnancy; Already using daily oral PrEP at the time of pregnancy diagnosis; Initiating injectable PrEP during pregnancy; Already using injectable PrEP (CAB-LA) at the time of pregnancy diagnosis
    PhasePhase 4
    Registry statusRecruiting